Huntington's disease biobank: remote monitoring study
Part of Brain & nervous system, Genetic & congenital, Mental health clinical trials.
This study is building a biobank to better understand Huntington's disease by using remote monitoring and deep phenotyping (collecting detailed health information). It may help develop better ways to track the disease and improve care for people with the Huntington's gene expansion.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a genetic test that shows you have the Huntington's disease gene expansion.
- If you have a movement disorder (like shaking or trouble walking) but tested negative for the Huntington's gene, you cannot join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses wearable sensors and a mobile app to track movement and other symptoms of Huntington's disease over time. It aims to see if digital tools can measure disease progression better than clinic visits alone.
This study uses smartphone and wearable sensors to track movement and thinking in people with Huntington's disease. It aims to find better ways to measure how the disease progresses in clinical trials.
This study follows people with Huntington's disease (or those who carry the gene) over time using online surveys. It aims to better understand how the disease progresses, which could help improve future care.
This study uses special brain imaging and memory/thinking tests to find early “markers” that can predict how Huntington’s disease will progress over time. You may qualify as someone with early-stage Huntington’s or as a healthy control, if you meet specific safety and scoring requirements.
This study is collecting tiny particles called extracellular vesicles from blood and spinal fluid to learn more about Huntington's disease. It aims to find better ways to measure the disease in people who have HD and in those who do not.
This study looks at specific “biomarkers” (measurable signs) found in cerebrospinal fluid, to better understand Huntington’s disease. The results may help researchers track the disease and improve future tests or treatments.
Hear when a new Huntington Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.